Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 285 across all filing types
Latest filing 2026-03-30 Major Shareholding Noti…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 95% confidence The document is a Korean statutory ‘임원ㆍ주요주주 특정증권등 소유상황보고서’, detailing changes in share ownership by a major shareholder (Kolon Corporation) in Kolon TissueGene, Inc., including quantities, acquisition dates, and percentages. This corresponds to a Major Shareholding Notification rather than an earnings release or management report.
2026-03-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a statutory ‘주식등의 대량보유상황보고서’ (Large Shareholding Status Report) filed under the Korean Capital Markets Act (reporting large shareholdings and threshold crossings). It details share quantities, ownership percentages, changes due to conversions and third-party allocations, and is clearly a major shareholding notification rather than financial results, management changes, or an annual report.
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 88% confidence The document is a corporate disclosure titled “사외이사의 선임·해임 또는 중도퇴임에 관한 신고” detailing the appointment and resignation of outside directors. It is a board/management change announcement, not a full annual or interim report, financial supplement, or other regulatory filing. Therefore it fits the Board/Management Information category (MANG).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed report of the results of the company’s Annual General Meeting held on 2026-03-26, showing resolutions adopted (financial statements approval, director and auditor elections, remuneration limits, stock options) along with voting percentages and detailed board member appointments. This aligns precisely with “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-26 Korean
코스닥시장상장외국법인외부감사인선임ㆍ해임신고서
Regulatory Filings Classification · 70% confidence The document is a regulatory notice regarding the appointment of a new external auditor for Kolon TissueGene, Inc. It is not an annual report, earnings release, or management change notice. It is also not the audit report itself but rather a filing to the stock exchange about auditor appointment. There is no specific category for auditor appointment, so this falls under the general regulatory filings category (RNS).
2026-03-25 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 92% confidence The document is a voluntary disclosure of the securities issuance result by KoLON TissueGene, detailing the type of security, issuance method (third-party allotment), planned vs. actual shares issued, amounts, and listing status. This is clearly an announcement of a new share issue/capital change. The appropriate classification is Share Issue/Capital Change (SHA).
2026-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.